Patrick O'Leary, PhD

Title(s)Specialist, HDF Comprehensive Cancer Ctr
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone--
ORCID ORCID Icon0000-0002-2919-5943 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University College Dublin, Dublin, IrelandPhD09/2013Cancer Biology
    University College Dublin , Dublin, IrelandBSc06/2009Pharmacology

    Collapse Overview 
    Collapse Overview
    Cancer biologist with a focus on using CRISPR screening to develop targeted therapeutics for cancers with mutations in DNA repair genes, and to study mechanisms of resistance to these therapies. Passionate about science education & outreach, strengthening community and exploring the outdoors.

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer. 2018 Oct 11; 18(1):965. Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. PMID: 30305055.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    2. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer. 2018 10; 119(7):873-884. Bajor M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, Firczuk M, Trzeciak L, Gaj P, Domagala A, Siernicka M, Zagozdzon A, Siedlecki P, Kniotek M, O'Leary PC, Golab J, Zagozdzon R. PMID: 30287919.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    3. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Res. 2015 Jun; 25(3):189-99. van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM. PMID: 25746038.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    4. Peroxiredoxin-1 protects estrogen receptor a from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Res. 2014 Jul 10; 16(4):R79. O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdzon R, Gallagher WM. PMID: 25011585.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    5. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. BMC Cancer. 2013 Apr 02; 13:175. O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM. PMID: 23547718.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    6. Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. BMC Cancer. 2012 May 30; 12:209. Zagozdzon AM, O'Leary P, Callanan JJ, Crown J, Gallagher WM, Zagozdzon R. PMID: 22646761.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    7. Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. Pigment Cell Melanoma Res. 2010 Aug; 23(4):542-53. Ryan D, Rafferty M, Hegarty S, O'Leary P, Faller W, Gremel G, Bergqvist M, Agnarsdottir M, Strömberg S, Kampf C, Pontén F, Millikan RC, Dervan PA, Gallagher WM. PMID: 20465595.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    Patrick's Networks
    Concepts (77)
    Derived automatically from this person's publications.
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _